Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer

NCT04826107 | Unknown Phase 2

• 1 other identifier: SYSA1501-CSP-003
• Study Type: interventional
• Target: 196
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study is an open-label, multicenter, phase II study to evaluate the efficacy and safety of DP303c injection in patients with HER2-positive advanced or metastatic gastric cancer.

Conditions

Gastric Cancer

Outcome Measures

Primary Outcomes (1)

• ORR(Objective Response Rate)

  The percentage of patients with a complete response (CR) or partial response (PR).

  Up to 2.5 years

Secondary Outcomes (5)

• PFS(Progression Free Survival)

  Up to 2.5 years

• OS(Overall Survival)

  Up to 2.5 years

• DCR(Disease Control Rate)

  Up to 2.5 years

• DOR(Duration of Response)

  Up to 2.5 years

• AEs and SAEs

  Up to 2.5 years

Study Arms (5)

Part 1: Dose-finding stage

EXPERIMENTAL

Patients with HER2-positive advanced or metastatic gastric cancer after receiving 1st-line treatment will be treated with DP303c injection at 2.0 mg/kg，2.5 mg/kg or 3.0 mg/kg every 3 weeks to determine the recommended dose.

Drug: DP303c treatment

Part 2: Cohort A

EXPERIMENTAL

Patients with HER2-positive advanced or metastatic gastric cancer after receiving 1st-line treatment will be treated with DP303c injection at the recommended dose.

Drug: DP303c treatment（second-line of HER2-positive）

Part 2: Cohort B

EXPERIMENTAL

Patients with HER2-positive advanced or metastatic gastric cancer after receiving ≥ 2nd-line treatment will be treated with DP303c injection at the recommended dose.

Drug: DP303c treatment （third-line of HER2-positive）

Part 2: Cohort C

EXPERIMENTAL

Patients with advanced or metastatic gastric cancer with HER2 low expression after receiving ≥1st-line treatment will be treated with DP303c injection at the recommended dose.

Drug: DP303c treatment（≥second-line of HER2 low expressing）

Part 2: Cohort D

EXPERIMENTAL

Patients with advanced or metastatic gastric cancer with HER2 low expression or HER2-positive expression after receiving ≥1st-line treatment will be treated with DP303c injection combined with PD-1/PD-L1 treatment.

Drug: DP303c + PD-1/PD-L1 treatment

Interventions

DP303c treatment DRUG

DP303c injection, every 3 weeks.

Part 1: Dose-finding stage

DP303c treatment（second-line of HER2-positive） DRUG

DP303c injection, every 3 weeks.

Part 2: Cohort A

DP303c treatment （third-line of HER2-positive） DRUG

DP303c injection, every 3 weeks.

Part 2: Cohort B

DP303c treatment（≥second-line of HER2 low expressing） DRUG

DP303c injection, every 3 weeks.

Part 2: Cohort C

DP303c + PD-1/PD-L1 treatment DRUG

DP303c injection + PD-1/PD-L1 injection, dose and frequency to be determined.

Part 2: Cohort D

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Volunteer to participate in this study and sign the informed consent form.
• Age ≥18 and ≤75 years, regardless of gender.
• Unresectable locally advanced, recurrent or metastatic gastric cancer (including gastric-esophageal junction adenocarcinoma) confirmed by histopathology and/or cytology; patients have received at least the first-line platinum or taxane based treatment (Patients who have progressed or recurred during neoadjuvant/adjuvant therapy or within 6 months after completion of treatment can participate. In this case, neoadjuvant/adjuvant therapy can be counted as one previous (1st-line) therapy); for each cohort in part 2, HER2-positive patients must also include trastuzumab or trastuzumab analog in the previous 1st-line therapy.
• Part 1 Progression on or after ≥ 1st-line treatment, HER2 positive. Part 2 Cohort A: Progression on or after 1st-line treatment, HER2 positive; Cohort B: Progression on or after ≥ 2nd-line of treatment, HER2 positive; Cohort C: Progression on or after ≥ 1st-line treatment, low expression of HER2; Cohort D: Progression on or after ≥ 1st-line treatment, HER2 low expression or HER2 positive.
• HER2 positive expression is defined as IHC 3+ or IHC 2+ with ISH test positive; HER2 low expression is defined as IHC 1+ or IHC 2+ with ISH test negative.
• Eastern Cooperative Oncology Group (ECOG) score of 0-1, and life expectancy ≥ 3 months.
• The function of major organs must meet the following criteria within 7 days before enrollment (Have not received blood transfusion, EPO, G-CSF or other medical supportive treatment within 14 days before the first dose of study drug):
• Absolute neutrophil count (ANC) ≥1.5×109 /L, Platelet ≥100×109 /L; Hemoglobin ≥90 g/L or ≥5.6 mmol/L; International normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN; Activated Partial Thromboplastin Time (APTT) ≤1.5×ULN; Creatinine clearance rate ≥30 mL/min (Calculated by Cockcroft-Gualt formula); Total bilirubin ≤1.5×ULN, or ≤3×ULN for patients with Gilbert's syndrome or liver metastasis; Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤2.5×ULN, or ≤5×ULN for patient.
• At least one measurable lesion at baseline per RECIST v1.1.
• Women of childbearing age must have a negative pregnancy test prior to study entry.
• Female and male patient of childbearing age must agree to take adequate contraceptive measures during the entire study period and through at least 6 months after the last dose of study drug.

You may not qualify if:

• Pregnant or breastfeeding women.
• Has not recovered from adverse reactions caused by previous anti-tumor treatments to ≤ grade 1 or baseline (refer to NCI CTCAE 5.0), except for alopecia, pigmentation and other toxicity judged no safety risk by the investigator.
• Patients who have previously received trastuzumab or trastuzumab analogues and have related toxicity, resulting in permanent discontinuation.
• Patients with history of allergy to any components (trastuzumab analogues, MMAE, sodium citrate dihydrate, citric acid monohydrate, polysorbate 20, sucrose, etc.) of DP303c.
• Patients with brain or pia mater metastasis; except for patients with central nervous system (CNS) metastases in the following conditions: untreated but asymptomatic, or progression-free status in imaging evidence for at least 4 weeks after treatment and not requiring hormone therapy for at least 4 weeks.
• Patients with pleural effusions or ascites that are difficult to control (the frequency of percutaneous drainage is more than once a week, or continuous drainage daily volume is ≥500 mL).
• The patient had acute and chronic gastrointestinal bleeding with hematemesis or melena within 4 weeks before the first administration of study drug (except for patients with only the fecal occult blood test positive, but without visible bleeding such as melena or hematemesis).
• Patients with gastrointestinal obstruction.
• Patients with dyspnea at rest induced by complications of advanced malignant tumors or need for continuous oxygen therapy.
• History of any other malignant tumors within five years (except for skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, local prostate cancer, cervical cancer in situ and other malignant tumors that have been radically removed and have not recurred).
• History of (non-infectious) interstitial pneumonia/pulmonary disease that requires steroid treatment, or current interstitial pneumonia/pulmonary disease, or suspected interstitial pneumonia/pulmonary disease that cannot be excluded by imaging examination; except for patients with radiation pneumonitis without clinical symptoms after 3 months of radiotherapy.
• Patients who currently have corneal diseases that require medication or surgical intervention, or have a history of serious corneal diseases, or are unwilling to stop wearing contact lenses during the study.
• History of congestive heart failure, unstable angina pectoris, arrhythmia.
• Patients with the following cardiac function defects at the time of enrollment:
• New York Heart Association (NYHA) heart function classification is level III or IV;

Sponsors & Collaborators

• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.: lead

MeSH Terms

Conditions

Stomach Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Study Officials

• Xu JianMing, Ph.D

  Chinese PLA General Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Xu JianMing, Ph.D

CONTACT

010-66939843; jmxu2003@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 22, 2021
• First Posted: April 1, 2021
• Study Start: August 1, 2021
• Primary Completion: August 1, 2024
• Study Completion: December 1, 2024
• Last Updated: April 1, 2021

Record last verified: 2021-03

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
• Time Frame: During the whole study.
• Access Criteria: All the researchers enrolled in this trial.